News

Public · Published

AdaptHealth 3Q 2026: Revenue $745.65M, Net income ($153.99M), EPS ($1.13) — 10-Q Summary

AdaptHealth reported third-quarter 2026 revenue of $745.65 million, up 10.9% year over year, but a net loss of $153.99 million versus net income of $24.51 million a year earlier. Diluted loss per share was $1.13, compared with earnings of $0.17 per share.

Published:

Updated:

What happened

AdaptHealth reported third-quarter 2026 revenue of $745.65 million, up 10.9% year over year, but a net loss of $153.99 million versus net income of $24.51 million a year earlier. Diluted loss per share was $1.13, compared with earnings of $0.17 per share.

Confirmed

Global impact / market context

Revenue growth alongside a sharp move from profit to loss suggests sales growth did not translate into stronger reported earnings in the quarter. If losses persist, they could limit cash available for operations or investment; the article does not explain the causes of the loss.

Analyst inference

The article also reports nine-month revenue growth across all segments and higher Respiratory adjusted EBITDA, a measure of operating performance before certain costs, but lower Sleep and Wellness adjusted EBITDA. This mixed picture points to differing results across businesses rather than uniform improvement.

Analyst inference

What to watch

  1. Watch for the company’s explanation of the quarterly loss and whether later results show that revenue growth is translating into improved earnings and cash available. Analyst inference
  2. The planned $235 million sale of Diabetes Health is expected to close in the first quarter of 2027, subject to customary conditions. Confirmed
  3. Track whether the rising share of capitated revenue, payment per patient rather than per service, changes revenue stability or costs as the contract develops. Analyst inference

Evidence

  • Original source link unavailable